ARAV Aravive Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARAV

Price (delayed)

$2.3

Market cap

$137.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.1

Enterprise value

$85.59M

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award ...

Highlights
The company's debt fell by 36% YoY and by 12% QoQ
The company's revenue rose by 23% YoY and by 6% QoQ
The company's quick ratio has surged by 66% QoQ but it fell by 26% YoY
The company's EPS rose by 11% QoQ but it fell by 8% YoY
The company's net income has shrunk by 95% YoY and by 27% QoQ
The company's equity has shrunk by 75% YoY and by 29% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://aravive.com
Peers: OVID

Key stats

What are the main financial stats of ARAV
Market
Shares outstanding
59.84M
Market cap
$137.64M
Enterprise value
$85.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.91
Price to sales (P/S)
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.37
Earnings
Revenue
$9.14M
EBIT
-$76.32M
EBITDA
-$75.44M
Free cash flow
-$65.09M
Per share
EPS
-$2.1
Free cash flow per share
-$1.79
Book value per share
$0.18
Revenue per share
$0.25
TBVPS
$1.71
Balance sheet
Total assets
$62.15M
Total liabilities
$51.5M
Debt
$4.08M
Equity
$10.66M
Working capital
$35.86M
Liquidity
Debt to equity
0.38
Current ratio
2.62
Quick ratio
2.54
Net debt/EBITDA
0.69
Margins
EBITDA margin
-825.6%
Gross margin
100%
Net margin
-835.3%
Operating margin
-775.3%
Efficiency
Return on assets
-130.4%
Return on equity
-321.5%
Return on invested capital
N/A
Return on capital employed
-190.6%
Return on sales
-835.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARAV stock price

How has the Aravive stock price performed over time
Intraday
1.32%
1 week
17.35%
1 month
22.99%
1 year
17.35%
YTD
74.24%
QTD
74.24%

Financial performance

How have Aravive's revenue and profit performed over time
Revenue
$9.14M
Gross profit
$9.14M
Operating income
-$70.84M
Net income
-$76.32M
Gross margin
100%
Net margin
-835.3%
The company's net income has shrunk by 95% YoY and by 27% QoQ
The operating income has dropped by 74% year-on-year and by 10% since the previous quarter
The company's net margin has shrunk by 59% YoY and by 20% QoQ
ARAV's operating margin is down by 42% year-on-year and by 3.7% since the previous quarter

Growth

What is Aravive's growth rate over time

Valuation

What is Aravive stock price valuation
P/E
N/A
P/B
12.91
P/S
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.37
The company's EPS rose by 11% QoQ but it fell by 8% YoY
The company's equity has shrunk by 75% YoY and by 29% QoQ
The price to sales (P/S) is 104% more than the last 4 quarters average of 4.5 but 23% less than the 5-year quarterly average of 11.9
The company's revenue rose by 23% YoY and by 6% QoQ

Efficiency

How efficient is Aravive business performance
Aravive's ROA has plunged by 164% YoY and by 30% from the previous quarter
The ROE has shrunk by 69% QoQ
The company's return on sales has shrunk by 59% YoY and by 20% QoQ

Dividends

What is ARAV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARAV.

Financial health

How did Aravive financials performed over time
Aravive's total assets is 21% higher than its total liabilities
ARAV's total liabilities has surged by 101% year-on-year and by 89% since the previous quarter
The company's quick ratio has surged by 66% QoQ but it fell by 26% YoY
The company's debt is 62% lower than its equity
Aravive's debt to equity has surged by 153% YoY and by 23% QoQ
The company's equity has shrunk by 75% YoY and by 29% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.